Peptide Therapeutics in Neurodegenerative Disorders

Author(s): Shashi Kant Tiwari, Rajnish K. Chaturvedi

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 23 , 2014

Become EABM
Become Reviewer
Call for Editor


Neurodegenerative diseases are characterized by selective and progressive degeneration of neuronal population in the brain, and associated behavioural, motor, psychiatric and cognitive impairments. Aggregation of pathogenic proteins, mitochondrial dysfunction, oxidative stress, transcriptional dysfunction and apoptosis play an important role in the pathogenesis of neurodegenerative disorders such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease and Amyotrophic lateral sclerosis. Therefore, novel therapies that target each of these mechanisms may be effective in abating the symptoms and slow down the onset and progression of neurodegenerative disorders. This review offers insights into the tremendous utility and versatility of peptides such as neurotrophins, neurotrophic factors (NGF, BDNF and GDNF), neuropeptides, mitochondrial targeted antioxidants/peptides, MitoQ, neurturin, and β-sheet breaker peptides to address the mechanisms and pathogenesis associated with neurodegenerative disorders.

Keywords: Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease, mitochondrial dysfunction, neurodegenerative diseases, neuropeptide, neurotrophin, Parkinson's disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 17 February, 2014
Page: [2610 - 2631]
Pages: 22
DOI: 10.2174/0929867321666140217125857
Price: $65

Article Metrics

PDF: 62